ArticleExperimental physiology2026
Therapeutic intervention with sinomenine and irisin to preserve cardiac function after ischaemia-reperfusion injury.
Article in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic intervention with sinomenine and irisin to preserve cardiac function after ischaemia-reperfusion injury.Experimental physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in reperfusion therapy, myocardial ischaemia-reperfusion (IR) injury remains a major clinical challenge. This study investigated whether a novel dual-target pre-conditioning strategy using sinomenine and irisin could enhance myocardial resistance against IR injury. Ninety male Sprague-Dawley rats were utilized. Protocol 1 evaluated cardioprotection by assigning rats to Sham, IR, sinomenine, irisin or a combination of both agents, with pharmacological pre-treatments administered for 7 days prior to surgery. To model IR injury in vivo, animals underwent 30 min surgical ligation of the left anterior descending coronary artery followed by 24 h reperfusion. Combined pre-treatment exerted superior protection, significantly reducing infarct size (P = 0.0187) and serum cardiotroponin-I (P = 0.0028), while preserving myocardial architecture. Echocardiography and haemodynamic monitoring confirmed significantly enhanced ejection fraction (P < 0.0001), fractional shortening (P = 0.0002), developed pressure (P = 0.0001), +dP/dt (P < 0.0001), and -dP/dt (P = 0.0003), alongside reduced left ventricular internal diameter at end-systole (P < 0.0001) and end-diastole (P = 0.0004), as well as decreased end-diastolic pressure (P = 0.0128) in the combination group. Protocol 2 investigated mechanisms using mitochondrial division inhibitor 1 (Mdivi-1). Combined pre-treatment mitigated oxidative stress, suppressed pro-inflammatory cytokines and inhibited the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome, evidenced by significant reductions in NLRP3, apoptosis-associated speck-like protein containing a CARD, and cleaved Gasdermin D. Conversely, it significantly upregulated PTEN-induced putative kinase 1 (PINK1) and Parkin. Notably, Mdivi-1 abrogated these benefits, confirming that the enhanced protection is mediated through the activation of the PINK1/Parkin-dependent mitophagy pathway. These results suggest that pharmacological pre-conditioning with sinomenine and irisin offers a potent strategy against IR injury by modulating the mitophagy-pyroptosis axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.